期刊文献+

低位直肠间质瘤腹腔镜辅助下的经内外括约肌间切除术 被引量:12

Laparoscopy- guided intersphincteric resection for low rectal stromal tumor
下载PDF
导出
摘要 目的:针对伊马替尼治疗下的低位直肠间质瘤,探讨腹腔镜辅助下经内外括约肌间切除术的安全性和可行性。方法:随访2007年1月至2011年1月9例低位直肠间质瘤患者,在术前接受伊马替尼治疗后行腹腔镜辅助下的经内外括约肌间切除术。结果:伊马替尼治疗前肿瘤大小为5~9 cm(中位值7.0 cm),治疗后肿瘤大小为2~4.5 cm(中位值3.5 cm)(P〈0.001)。治疗3~24个月(中位值7个月)行腹腔镜辅助下的经内外括约肌间切除术,住院时间5~9天(中位值7天),所有患者均行保护性造口,术后3个月行造口还纳术。Wexner评分在伊马替尼治疗前为1~4分(中位值2分),治疗后为1~5分(中位值2分)(P=0.397);造口还纳术后Wexner评分4~9分(中位值7分),较术前明显增加(P〈0.001),术后1年为1~5分(中位值2分),与术前比较差异无统计学意义(P=0.842)。术后有6例继续服用伊马替尼24~30个月。1例未继续服用伊马替尼,患者在30个月时出现盆底复发。结论:腹腔镜辅助下的经内外括约肌间切除术对于低位直肠间质瘤的治疗是安全可行的。 Objective: To investigate the clinical security and feasibility of neoadjuvant chemotherapy with imatinib following laparoscopy-guided intersphincteric resection for patients with gastrointestinal stromal tumor of the low rectum(GSTLR). Methods: Clinical data of nine patients with GSTLR who were admitted to the Shengjing Hospital between January 2007 and January 2011 were reviewed. These patients were treated with neoadjuvant imatinib chemotherapy after laparoscopic intersphincteric resection. Results: Prior to neoadjuvant chemotherapy, the tumor diameter ranged between from 5 cm to 9 cm(median=7.0 cm). After imatinib chemotherapy, the tumor diameter decreased to 2-4.5 cm(median=3.5 cm, P0.001). Laparoscopic surgery through intersphincteric resection was performed after imatinib treatment for 3-24 months(median=7 months). All patients received a protective stoma, which was closed 3months after the surgery. The Wexner scale scores ranged from 1 and 4(median=2) prior to neoadjuvant imatinib chemotherapy and changed to 1-5(median=2) after the chemotherapy(P=0.397). After stomal closure operation, the scores significantly increased to 4-9(median=7, P0.001) but were not statistically significantly different from those before the therapy. One year after laparoscopic surgery,the Wexner scale scores ranged from 1 to 5(median=2, P=0.842). Six patients were treated with imatinib for 24 and 30 months after laparoscopic surgery. Recurrence in pelvis occurred in only one patient, who ceased imatinib administration at the 30 th month after the surgery. Conclusions: Laparoscopic surgery through intersphincteric resection was secure and feasible and thus could be used for treatment of GSTLR.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2015年第5期292-296,共5页 Chinese Journal of Clinical Oncology
基金 辽宁省自然科学基金项目(编号:2013010098)资助~~
关键词 直肠间质瘤 腹腔镜 经内外括约肌间切除术 rectal stromal tumor laparoscopy intersphincteric resection
  • 相关文献

参考文献1

二级参考文献10

  • 1Vander Noot MR 3rd,Eloubeidi MA,Chen VK,EltoumI,Jhala D,Jhala N,Syed S,Chhieng DC.Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound- guided fine-needle aspiration biopsy[].Cancer.2004 被引量:1
  • 2Miettinen M,Sarlomo-Rikala M,Lasota J.Gastrointestinal stromal tumors: recent advances in understanding of their biology[].Human Pathology.1999 被引量:1
  • 3Miettinen M,Furlong M,Sarlomo-Rikala M,et al.Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases[].American Journal of Surgical Pathology.2001 被引量:1
  • 4H Joensuu,PJ Roberts,M Sarlomo-Rikala,LC Andersson,P Tervahartiala,D Tuveson,S Silberman,R Capdeville,S Dimitrijevic,B Druker,GD Demetri.Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor[].The New England Journal of Medicine.2001 被引量:1
  • 5T Aparicio,V Boige,JC Sabourin,P Crenn,M Ducreux,A Cesne,S Bonvalot.Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours[].European Journal of Surgical Oncology.2004 被引量:1
  • 6Maria Debiec-Rychter Jan Cools Herlinde Dumez Raf Sciot Michel Stul Nicole Mentens Hilde Vranckx Bartosz Wasag.Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants[].Gastroenterology.2005 被引量:1
  • 7Antonescu,CR,Besmer,P,Guo,T,Arkun,K,Hom,G,Koryotowski,B,Leversha,MA,Jeffrey,PD,Desantis,D,Singer,S,Brennan,MF,Maki,RG.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation[].Clinical Cancer Research.2005 被引量:1
  • 8Wardelmann,E,Thomas,N,Merkelbach-Bruse,S,Pauls,K,Speidel,N,Büttner,R,Bihl,H,Leutner,C,Heinicke,T,Hohenberger,P.Acquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations[].The Lancet Oncology.2005 被引量:1
  • 9Miettinen M,Lasota J.Gastrointestinal stromal tumors: pathology and prognosis at different sites[].Seminars in Diagnostic Pathology.2006 被引量:1
  • 10Williams DB,Sahai AV,Aabakken L,Penman ID,van Velse A,Webb J,Wilson M,Hoffman BJ,Hawes RH.Endoscopic ultrasound guided fine needle aspiration biopsy:a large single centre experience[].Gut.1999 被引量:1

共引文献5

同被引文献67

引证文献12

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部